Minjuvi® (tafasitamab) has been added to the Pharmaceutical Benefits Scheme (PBS) in combination with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma. The listing marks a new publicly funded treatment option for patients whose disease has returned or has not responded to earlier therapy.
The announcement describes the regimen as the first and only chemotherapy-free, dual-targeted immunotherapy combination on the PBS that targets both CD19 and CD20. That makes it a notable development in follicular lymphoma care, where treatment decisions often depend on prior response and the need for alternatives to chemotherapy-based approaches.
Under the listed regimen, tafasitamab is used alongside rituximab and lenalidomide, bringing together multiple immune-based strategies in one treatment pathway. The PBS inclusion is significant because reimbursement can improve practical access for eligible adults and support broader use in routine clinical care.
For people living with relapsed or refractory follicular lymphoma, expanded access to a chemotherapy-free option may widen the range of available management strategies. The listing also highlights growing momentum behind immunotherapy combinations in blood cancer treatment.
